Early CKD Prospective Follow up Study

ABSTRACT In early-stage CKD (stages 1–3) study aimed to investigate the prognostic utility of suPAR and IgM-uria compared to current standard biomarkers (eGFR and urine albumin-to-creatinine ratio (ACR)). This prospective cohort study included a consecutive sample of patients with CKD stages 1–3 who were recruited from a medical specialty outpatient clinic between July 1, 2012, and June 16, 2016. Participants were followed until December 2023 to assess the primary outcomes. Major adverse cardiovascular outcomes (MACEs) included a composite of myocardial infarction (MI), unstable angina (UA), stroke, transient ischemic attack (TIA), or death due to cardiovascular disease (CVD). Kidney failure outcomes were defined as progression to ESKD, CKD stage 5, or a sustained decline in eGFR ≥40%.